FUROSEMIDE Drug Patent Profile
✉ Email this page to a colleague
When do Furosemide patents expire, and what generic alternatives are available?
Furosemide is a drug marketed by Abraxis Pharm, Accord Hlthcare, Am Regent, Amneal Pharms Co, Areva Pharms, Astrazeneca, Avet Lifesciences, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Igi Labs Inc, Intl Medication, Mankind Pharma, Marsam Pharms Llc, Meitheal, Saba Ilac Sanayive, Sagent, Smith And Nephew, Warner Chilcott, Watson Labs, Wockhardt, Wyeth Ayerst, Pharmobedient Cnsltg, Ani Pharms, Chartwell Rx, Epic Pharma Llc, Graviti Pharms, Ipca Labs Ltd, Kalapharm, Leading, Mylan, Prinston Inc, Strides Pharma, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, and Watson Labs Teva. and is included in sixty-five NDAs.
The generic ingredient in FUROSEMIDE is furosemide. There are twenty-two drug master file entries for this compound. Fifty-eight suppliers are listed for this compound. Additional details are available on the furosemide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Furosemide
A generic version of FUROSEMIDE was approved as furosemide by MYLAN on October 29th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FUROSEMIDE?
- What are the global sales for FUROSEMIDE?
- What is Average Wholesale Price for FUROSEMIDE?
Summary for FUROSEMIDE
US Patents: | 0 |
Applicants: | 40 |
NDAs: | 65 |
Finished Product Suppliers / Packagers: | 56 |
Raw Ingredient (Bulk) Api Vendors: | 137 |
Clinical Trials: | 269 |
Patent Applications: | 2,946 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for FUROSEMIDE |
Drug Sales Revenues: | Drug sales revenues for FUROSEMIDE |
What excipients (inactive ingredients) are in FUROSEMIDE? | FUROSEMIDE excipients list |
DailyMed Link: | FUROSEMIDE at DailyMed |
Recent Clinical Trials for FUROSEMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) | N/A |
University of Delaware | N/A |
University Hospital, Tours | Phase 3 |
Pharmacology for FUROSEMIDE
Drug Class | Loop Diuretic |
Physiological Effect | Increased Diuresis at Loop of Henle |
Medical Subject Heading (MeSH) Categories for FUROSEMIDE
Anatomical Therapeutic Chemical (ATC) Classes for FUROSEMIDE
US Patents and Regulatory Information for FUROSEMIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharm Inds Inc | FUROSEMIDE | furosemide | TABLET;ORAL | 091258-001 | Apr 1, 2014 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Chartwell Rx | FUROSEMIDE | furosemide | TABLET;ORAL | 018413-001 | Nov 30, 1983 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Watson Labs | FUROSEMIDE | furosemide | INJECTABLE;INJECTION | 070604-001 | Jan 2, 1987 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Watson Labs | FUROSEMIDE | furosemide | TABLET;ORAL | 018369-002 | May 14, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Graviti Pharms | FUROSEMIDE | furosemide | TABLET;ORAL | 216629-003 | Oct 17, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |